4-(hydroxymethyl)piperidine-4-carbonitrile | 1207177-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(hydroxymethyl)piperidine-4-carbonitrile
• CAS: 1207177-75-0
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: FGSXRNOVQKOOFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  56
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(hydroxymethyl)piperidine-4-carbonitrile 在 盐酸 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 4,5-dichloro-2-[[4-(hydroxymethyl)-4-[(pyrrolidin-1-yl)carbonyl]piperidin-1-yl]methyl]phenol
  参考文献：
  名称：

  [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE EN TANT QUE BLOQUEURS DES CANAUX D'AGITATEUR POTASSIQUE KV1.3

  摘要：

  公开号：

  WO2021071812A8
• 作为产物：
  描述：

  4-氰基-4-(羟基甲基)哌啶-1-羧酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-(hydroxymethyl)piperidine-4-carbonitrile
  参考文献：
  名称：

  [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE EN TANT QUE BLOQUEURS DES CANAUX D'AGITATEUR POTASSIQUE KV1.3

  摘要：

  公开号：

  WO2021071812A8

文献信息

• [EN] ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES
  申请人：ADORX THERAPEUTICS LTD

  公开号：WO2022023772A1

  公开（公告）日：2022-02-03

  The present invention relates to compounds of formula (I) shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a and/or A2b receptor activity is implicated, such as, for example, cancer.

  本发明涉及如下所示的式(I)化合物：其中R1、R2、R3、R4、R5和R6在申请中各自定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗腺苷A2a和/或A2b受体活性参与的疾病或病况中的用途，例如癌症。
• IMIDAZO[1,2-a]PYRIDINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：US20130053363A1

  公开（公告）日：2013-02-28

  [Problem] To provide a compound useful as medicine having PDE4B inhibitory activity, in particular, as an active ingredient of a composition for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like. [Measures for Solution] The present inventors examined compounds having PDE4B inhibitory activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had a superior PDE4B inhibitory activity, thereby completing the present invention. The imidazo[1,2-a]pyridine derivative can be used as an agent for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like.

  [问题]提供一种作为药物有PDE4B抑制活性的化合物，特别是作为治疗或预防精神分裂症、阿尔茨海默病、痴呆、抑郁症等组合物的活性成分。[解决方案措施]本发明人研究了具有PDE4B抑制活性的化合物，发现三环或四环咪唑[1,2-a]吡啶衍生物或其盐具有卓越的PDE4B抑制活性，从而完成了本发明。咪唑[1,2-a]吡啶衍生物可用作治疗或预防精神分裂症、阿尔茨海默病、痴呆、抑郁症等的药物。
• Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors
  作者：Eric J. Gilbert、Guowei Zhou、Michael K.C. Wong、Ling Tong、Bandarpalle B. Shankar、Chunli Huang、Joseph Kelly、Brian J. Lavey、Stuart W. McCombie、Lei Chen、Razia Rizvi、Youhao Dong、Youheng Shu、Joseph A. Kozlowski、Neng-Yang Shih、R. William Hipkin、Waldemar Gonsiorek、Asra Malikzay、Charles A. Lunn、Len Favreau、Daniel J. Lundell

  DOI：10.1016/j.bmcl.2009.11.084

  日期：2010.1

  The triaryl bis-sulfone 1 was modified by converting the aryl A-ring to a piperidine ring. The piperidine ring was further elaborated to a spirocyclopropyl piperidine moiety. The effect on CB2 binding potency, rat calcium channel affinity, and CYP 2C9 inhibition is described. (C) 2009 Elsevier Ltd. All rights reserved.
• SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：EP3297989A1

  公开（公告）日：2018-03-28
• ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
  申请人：D. E. Shaw Research, LLC

  公开号：US20220411367A1

  公开（公告）日：2022-12-29

  A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.